Journal articles on the topic 'And macitentan'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'And macitentan.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Martynyuk, T. V., and A. M. Aleevskaya. "Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan." Kardiologiia 60, no. 7 (2020): 28–35. http://dx.doi.org/10.18087/cardio.2020.7.n1136.
Full textRahaghi, Franck F., Hassan M. Alnuaimat, Rana L. A. Awdish, et al. "Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus document." Pulmonary Circulation 7, no. 3 (2017): 702–11. http://dx.doi.org/10.1177/2045893217721695.
Full textTynan, Timothy, Kathryn Hird, Tara Hannon, and Eli Gabbay. "Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan." Journal of International Medical Research 47, no. 5 (2019): 2177–86. http://dx.doi.org/10.1177/0300060519840130.
Full textMartynuk, T. V., S. N. Nakonechnikov, and I. Ye Chazova. "MACITENTAN: THE EVOLUTION OF THE CLASS ENDOTHELIN RECEPTOR ANTAGONISTS TO IMPROVE EFFICACY AND SAFETY OF PAH TREATMENT." Eurasian heart journal, no. 2 (June 30, 2013): 15–26. http://dx.doi.org/10.38109/2225-1685-2013-2-15-26.
Full textHanibuchi, Masaki, Sun-Jin Kim, Kenji Otsuka, et al. "Eradication of experimental brain metastases of human non-small cell lung cancer by macitentan, a dual antagonist of the endothelin A and B receptor, combined with paclitaxel." Journal of Clinical Oncology 30, no. 30_suppl (2012): 92. http://dx.doi.org/10.1200/jco.2012.30.30_suppl.92.
Full textShinohara, Tsutomu, Hirofumi Sawada, Shoichiro Otsuki, et al. "Macitentan reverses early obstructive pulmonary vasculopathy in rats: early intervention in overcoming the survivin-mediated resistance to apoptosis." American Journal of Physiology-Lung Cellular and Molecular Physiology 308, no. 6 (2015): L523—L538. http://dx.doi.org/10.1152/ajplung.00129.2014.
Full textMartynyuk, T. V., S. N. Nakonechnikov, and I. Ye Chazova. "OPTIMIZATION OF SPECIFIC THERAPY FOR PULMONARY ARTERIAL HYPERTENSION: THE POSSIBILITIES OF USING ENDOTHELIN RECEPTOR ANTAGONISTS." Eurasian heart journal, no. 2 (June 30, 2017): 20–27. http://dx.doi.org/10.38109/2225-1685-2017-2-20-27.
Full textTrivedi, Jahanvee K., Chirag J. Patel, and M. M. Patel. "RP-HPLC METHOD DEVELOPMENT AND VALIDATION OF MACITENTAN WITH ITS KNOWN AND UNKNOWN DEGRADATION IMPURITIES IN ITS TABLET DOSAGE FORM." International Journal of Applied Pharmaceutics 10, no. 5 (2018): 81. http://dx.doi.org/10.22159/ijap.2018v10i5.26211.
Full textVachiéry, Jean-Luc, Marion Delcroix, Hikmet Al-Hiti, et al. "Macitentan in pulmonary hypertension due to left ventricular dysfunction." European Respiratory Journal 51, no. 2 (2018): 1701886. http://dx.doi.org/10.1183/13993003.01886-2017.
Full textQin, Jinlv, Guizuo Wang, and Dong Han. "Benefits of Macitentan in Patients with Pulmonary Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Global Heart 18, no. 1 (2023): 58. http://dx.doi.org/10.5334/gh.1274.
Full textAlbayrak, Mevlut, and Alptug Atila. "Development and Validation of Novel UPLC-MS/MS Method for the Analysis of Macitentan in Pharmaceutical Formulations." Current Pharmaceutical Analysis 15, no. 5 (2019): 554–59. http://dx.doi.org/10.2174/1573412915666190314142531.
Full textMorales-Loredo, Humberto, David Jones, Adelaeda Barrera, et al. "A dual blocker of endothelin A/B receptors mitigates hypertension but not renal dysfunction in a rat model of chronic kidney disease and sleep apnea." American Journal of Physiology-Renal Physiology 316, no. 5 (2019): F1041—F1052. http://dx.doi.org/10.1152/ajprenal.00018.2019.
Full textSimonneau, Gérald, Richard N. Channick, Marion Delcroix, et al. "Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN." European Respiratory Journal 46, no. 6 (2015): 1711–20. http://dx.doi.org/10.1183/13993003.00364-2015.
Full textMoisseeva, O. M., and A. V. Rudakova. "Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension." Terapevticheskii arkhiv 89, no. 3 (2017): 72–77. http://dx.doi.org/10.17116/terarkh201789372-77.
Full textMamazhakypov, Argen, Astrid Weiß, Sven Zukunft, et al. "Effects of macitentan and tadalafil monotherapy or their combination on the right ventricle and plasma metabolites in pulmonary hypertensive rats." Pulmonary Circulation 10, no. 4 (2020): 204589402094728. http://dx.doi.org/10.1177/2045894020947283.
Full textBelge, Catharina, and Marion Delcroix. "Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience." Therapeutic Advances in Respiratory Disease 13 (January 2019): 175346661882344. http://dx.doi.org/10.1177/1753466618823440.
Full textSheffer, Joe. "Macitentan: Endothelin receptor antagonist." Pharmacy Today 19, no. 12 (2013): 50. http://dx.doi.org/10.1016/s1042-0991(15)31059-8.
Full textPatel, Trina, and Kate McKeage. "Macitentan: First Global Approval." Drugs 74, no. 1 (2013): 127–33. http://dx.doi.org/10.1007/s40265-013-0156-6.
Full textZebadúa, Rodrigo, Andrea Priscila Hernández-Pérez, Antonio García, et al. "Macitentan in the treatment of pulmonary arterial hypertension." Future Cardiology 17, no. 1 (2021): 49–58. http://dx.doi.org/10.2217/fca-2020-0012.
Full textArkhipova, O. A., T. V. Martynyuk, and I. E. Chazova. "A clinical case of long-term macitentan therapy in a female patient with idiopathic pulmonary hypertension." Terapevticheskii arkhiv 88, no. 12 (2016): 88–93. http://dx.doi.org/10.17116/terarkh2016881288-93.
Full textBenza, Raymond L., Cassandra A. Lickert, Lin Xie, et al. "Comparative effectiveness of endothelin receptor antagonists on mortality in patients with pulmonary arterial hypertension in a US Medicare population: a retrospective database analysis." Pulmonary Circulation 10, no. 4 (2020): 204589402095415. http://dx.doi.org/10.1177/2045894020954158.
Full textSteven, Sebastian, Matthias Oelze, Michael Hausding, et al. "The Endothelin Receptor Antagonist Macitentan Improves Isosorbide-5-Mononitrate (ISMN) and Isosorbide Dinitrate (ISDN) Induced Endothelial Dysfunction, Oxidative Stress, and Vascular Inflammation." Oxidative Medicine and Cellular Longevity 2018 (December 27, 2018): 1–17. http://dx.doi.org/10.1155/2018/7845629.
Full textCutolo, Maurizio, Paola Montagna, Renata Brizzolara, et al. "Effects of Macitentan and Its Active Metabolite on Cultured Human Systemic Sclerosis and Control Skin Fibroblasts." Journal of Rheumatology 42, no. 3 (2015): 456–63. http://dx.doi.org/10.3899/jrheum.141070.
Full textRetuerto-Guerrero, M., C. Moriano, I. Castellví, B. Atienza-Mateo, and E. Diez Álvarez. "AB0921 EFFICACY AND SAFETY OF MACITENTAN IN REFRACTORY DIGITAL ULCERS." Annals of the Rheumatic Diseases 82, Suppl 1 (2023): 1677.2–1678. http://dx.doi.org/10.1136/annrheumdis-2023-eular.6359.
Full textLiu, Zhong-Yu, Man-Ting Au, Tian-Wei He, et al. "Less Vertebral Bone Mass after Treatment with Macitentan in Mice: A Pilot Study." BioMed Research International 2019 (February 19, 2019): 1–6. http://dx.doi.org/10.1155/2019/2075968.
Full text"Macitentan." Reactions Weekly 1840, no. 1 (2021): 247. http://dx.doi.org/10.1007/s40278-021-90390-x.
Full text"Macitentan." Reactions Weekly 1914, no. 1 (2022): 279. http://dx.doi.org/10.1007/s40278-022-18865-6.
Full text"Macitentan." Reactions Weekly 2017, no. 1 (2024): 272. http://dx.doi.org/10.1007/s40278-024-63248-5.
Full text"MACITENTAN." Drug Data Report 31, no. 2 (2009): 143. http://dx.doi.org/10.1358/ddr.2009.031.02.1287227.
Full text"Macitentan." Reactions Weekly 1693, no. 1 (2018): 313. http://dx.doi.org/10.1007/s40278-018-43203-3.
Full text"Macitentan." Reactions Weekly 1641, no. 1 (2017): 160. http://dx.doi.org/10.1007/s40278-017-27074-1.
Full text"Macitentan." Reactions Weekly 1653, no. 1 (2017): 200. http://dx.doi.org/10.1007/s40278-017-30628-y.
Full text"Macitentan." Reactions Weekly 1699, no. 1 (2018): 186. http://dx.doi.org/10.1007/s40278-018-45454-1.
Full text"Macitentan." Reactions Weekly 1600, no. 1 (2016): 135. http://dx.doi.org/10.1007/s40278-016-17220-y.
Full text"Macitentan." Reactions Weekly 1668, no. 1 (2017): 256. http://dx.doi.org/10.1007/s40278-017-35728-7.
Full text"Macitentan." Reactions Weekly 1675, no. 1 (2017): 154. http://dx.doi.org/10.1007/s40278-017-37922-x.
Full text"Macitentan." Reactions Weekly 1761, no. 1 (2019): 237. http://dx.doi.org/10.1007/s40278-019-64609-5.
Full text"Macitentan." Reactions Weekly 1966, no. 1 (2023): 202. http://dx.doi.org/10.1007/s40278-023-43655-9.
Full text"Macitentan." Reactions Weekly 2069, no. 1 (2025): 215. https://doi.org/10.1007/s40278-025-86873-7.
Full textWeathers, Shiao-Pei, Julie Rood-Breithaupt, John de Groot, et al. "Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma." Neuro-Oncology Advances 3, no. 1 (2021). http://dx.doi.org/10.1093/noajnl/vdab141.
Full text"Macitentan/sildenafil." Reactions Weekly 1844, no. 1 (2021): 268. http://dx.doi.org/10.1007/s40278-021-91715-7.
Full text"Macitentan/selexipag." Reactions Weekly 1864, no. 1 (2021): 220. http://dx.doi.org/10.1007/s40278-021-99150-4.
Full text"Macitentan/sildenafil." Reactions Weekly 1929, no. 1 (2022): 385. http://dx.doi.org/10.1007/s40278-022-26009-4.
Full text"Epoprostenol/Macitentan." Reactions Weekly 2029, no. 1 (2024): 264. http://dx.doi.org/10.1007/s40278-024-68442-z.
Full text"Macitentan/Sildenafil." Reactions Weekly 2016, no. 1 (2024): 268. http://dx.doi.org/10.1007/s40278-024-62761-9.
Full text"Macitentan/selexipag." Reactions Weekly 1933, no. 1 (2022): 270. http://dx.doi.org/10.1007/s40278-022-28221-5.
Full text"Macitentan/treprostinil." Reactions Weekly 1787, no. 1 (2020): 332. http://dx.doi.org/10.1007/s40278-020-73970-4.
Full text"Macitentan/riociguat." Reactions Weekly 1745, no. 1 (2019): 173. http://dx.doi.org/10.1007/s40278-019-59336-x.
Full text"Macitentan/sildenafil." Reactions Weekly 1932, no. 1 (2022): 369. http://dx.doi.org/10.1007/s40278-022-27734-x.
Full text"Macitentan/tadalafil." Reactions Weekly 1932, no. 1 (2022): 370. http://dx.doi.org/10.1007/s40278-022-27735-x.
Full text